Our commitment to consumer healthcare
In consumer healthcare, Ipsen offers treatments for gastrointestinal disorders, neurodegenerative pathologies, and rheumatology.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
- @IpsenGroup Let's Talk About NETs https://t.co/cLypB9ZCaS #NETCancer Video and Infographics #NetCancerDay
- @IpsenGroup #NETCancer is often a silent disease. Ipsen supports awareness of NET and raise awareness for #NETCancerDay… https://t.co/CgDB7nCRhF
- @IpsenGroup RT @ICOnoticies: Avui, gràcies a @IpsenGroup i @Netespana hem donat més visibilitat als tumors neuroendocrins a l'ICO l'Hospitalet. Ha qued…
- @IpsenGroup David Meek CEO Ipsen #FTPharma "As a top 20 oncology company we need to work together to address many of the challenges ahead" @ftliveHealth